Comparison of two direct neutralizing assay formats using recombinant follicle-stimulating hormone as agonist

Journal of Immunological Methods

Volumn 400-401, Issue 1, 2013, Pages 87-96

  Ryding, J ^a   Hjertberg, E ^a   Rasmussen, B B ^a  

^a Ferring Pharmaceuticals AS   (Denmark)

Author keywords

Antibodies; Bioassay; Cell based; Format; NAb; Neutralizing

Indexed keywords

NEUTRALIZING ANTIBODY; RECOMBINANT FOLLITROPIN;

ACCURACY; ANTIBODY BLOOD LEVEL; ARTICLE; ASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; FALSE NEGATIVE RESULT; FEMALE; FIXED CONCENTRATION ASSAY; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTERMETHOD COMPARISON; PRIORITY JOURNAL; VALIDATION STUDY; VARIABLE CONCENTRATION ASSAY;

EID: 84888431066     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2013.10.008     Document Type: Article

References (20)

1. Baltrukonis D.J., Finco-Kent D., Kawabata T.T., Poirier M., LeSauteur L. Development and validation of a quasi-quantitative bioassay for neutralizing antibodies against CP-870,893. J. Immunotoxicol. 2006, 3(3):157.
2. Casadevall N., Nataf J., Viron B., Kolta A., Kiladjian J.J., Martin-Dupont P., et al. Pure red cell aplasia and anti-erythropoietin antibodies against human erythropoietin in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002, 346:469.
3. Cole L.A. hCG, five independent molecules. Clin. Chim. Acta Int. J. Clin. Chem. 2012, 413(1-2):48.
4. Eglen R.M. Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev. Technol. 2002, 1(1 Pt 1):97. (Nov).
5. European Medicines Agency Committee for Medicinal Products (CHMP) for human use; guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006 2007.
6. Graham F.L., Smiley J., Russell W.C., Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977, 36(1):59.
7. Gupta S., Indelicato S., Jethwa V., Kawabata T., Kelley M., Mire-Sluis M., et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Methods 2007, 321:1.
8. Gupta S., Devanarayan V., Finco D., Gunn G.R., Kirshner S., Richards S., Rup B., et al. J. Pharm. Biomed. Anal. 2011, 55(5):878. (Jul 15).
9. Koren E., Smith H.W., Shores E., Shankar G., Finco-Kent D., Rup B., et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J. Immunol. Methods 2008, 333:1.
10. Lam R., Farrell R., Aziz T., Gibbs E., Giovannoni G., Grossberg S., Oger J. Validating parameters of a luciferase gene reporter assay to measure neutralizing antibodies to INFb in MS patients. J. Immunol. Methods 2008, 336(2):113. (Jul 31).
11. Li J., Yang C., Yuping X., Bertino A., Glaspy J., Roberts M., et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241.
12. Ponce R., Abad L., Amaravadi L., Gelzleichter T., Gore E., Green J., Gupta S., et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 2009, 54:164.
13. Rini B., Wadhwa M., Bird C., Fagerberg J., Gaines-Das R., Thorpe R. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine 2005, 29:56.
14. Shankar G., Devanarayan V., Amaravadi L., Smith H., Barrett Y.C., Bowsher R., et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 2008, 48:1267.
15. Storring P.L., Gaines Das R.E. The fourth International Standard for Human Urinary FSH and LH: specificities of LH seminal vesicle weight gain assays in the collaborative study differ between laboratories. J. Endocrinol. 2001, 171:119.
16. U.S.Food and Drug Administration Guidance for Industry: assay development for immunogenicity testing of therapeutic proteins http://www/fda/gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/defaault.htm.
17. van de Weert M., Horn Moller E. Immunogenicity of Biopharmaceuticals 2008, Springer-Verlag, New York Inc., USA, (ISBN10:0387758402).
18. Wadhwa M., Bird C., Fagerberg J., Gaines-Das R., Ragnhammar P., Mellstedt H., Thorpe R. Production of neutralizing granulocyte-macrophage colony stimulating factor (GM-CSF) antibodies in carcinoma patients following GM-CSF combination therapy. Clin. Exp. Immunol. 1996, 104:351.
19. White J.T., Argento Martell L., Prince W.S., Boyer R., Crockett L., Cox C., et al. Comparison of neutralizing antibody assays for receptor binding and enzyme activity of the Nagalzyme (Galsulfase). AAPS J. Sep. 2008, 10(3):439.
20. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 1999, 4(2):67.